Scientists at the University of Oxford in the UK have launched a new clinical trial to test a vaccine to protect against “devastating” Marburg virus.

This is the first-in-human trial of the ChAdOx1 Marburg vaccine, which has been developed and manufactured by researchers at the University of Oxford.

Marburg virus is a highly virulent disease in the same family as Ebola that is fatal in up to 88% of cases and has no approved vaccines or treatments.

Forty-six people aged 18 to 55 will participate in the trial, which will be led by the Oxford Vaccine Group.

The research was funded by the Department of Health and Social Care as part of the UK Vaccine Network (UKVN), a UK Aid programme to develop vaccines for diseases with epidemic potential in low and middle-income countries.

Professor Teresa Lambe OBE, the trial’s Lead Scientific Investigator and Professor of Vaccinology at Oxford Vaccine Group and the Pandemic Sciences Institute, University of Oxford, said: “Although outbreaks of Marburg virus have historically been small, this devastating disease has started to spread even further and the potential to cause a pandemic and inflict suffering on many is a real concern.”

Marburg virus disease is a zoonotic disease which can be transmitted between humans through direct contact and bodily fluids, often meaning health workers are those most likely to get infected.

The disease can lead to haemorrhagic fever (impaired blood clotting leading to widespread bleeding) and encephalitis (inflammation of the brain).

It is one of the diseases designated by the World Health Organization as a priority disease for research and development, and it is also listed as a high consequence infectious disease by the UK Health Security Agency.

Diana Spencer, Senior Digital Content Editor, DDW